专注于开发基于新型 T 细胞免疫疗法的临床阶段生物技术公司 Virion Therapeutics 近日在北京举办的2025年亚太肝病学会年会（APASL2025）上公布了旗下一款用于慢性乙型肝炎治疗的在研免疫疗法 VRON-0200 ...

AT-61; AT-130 Inhibit HBV virion production by inappropriate assembly of capsids (no clinical data available yet) Induces structural changes in HBV capsids; initiates virion assembly at wrong ...

面对如此积极的研究进展，慢乙肝患者及其家属都感到无比欣喜。对于这一群体而言，能够有新的治疗选择，无疑是更为重要的希望。随着后续临床数据的逐步公布，VRON-0200的应用前景将愈加明朗，有望为数以百万计的慢乙肝患者打开一扇新窗。

In addition to HBsAg, other viral markers such as hepatitis B core-related antigen (HBcrAg) are available, but their potential association with HBV-specific immune responses is not defined yet, which ...

However, its role in hepatitis B virus (HBV) replication has not been previously studied. In this study, we demonstrate that RNF5 effectively inhibits HBV replication by promoting the degradation of ...

Children and adults vaccinated on the recommended hep B series are afforded lifelong protection against the hepatitis B virus (HBV), a highly infectious virus that attacks the liver. Vaccination is ...

2 German Center for Infection Research, Hamburg-Lübeck-Borstel-Riems, Munich and Heidelberg sites, Germany Objectives A major goal of curative hepatitis B virus (HBV) treatments is the reduction or ...

GSK has revealed updated results from its phase 2b trial of its antisense drug for hepatitis B virus (HBV) infections, which reveal a sharp decline in the proportion of patients with undetectable ...

Antimycobacterial susceptibility testing methods for natural products research Sánchez, Juan Gabriel Bueno Kouznetsov, Vladimir V.